CK 2289 is an inhibitor of type III cyclic 3'5' -adenosine monophosphate phosphodiesterase with potential use in the treatment of congestive heart failure.
Enoximone sulfoxide is a selective phosphodiesteraseIII (PDE3) inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. Enoximone prevents the degradation of cAMP by PDE, which prolongs signal transduction and its subsequent effects. It is used in patients with congestive heart failure.
Moxaverine hydrochloride is a derivative of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma.